UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 1217, 2025

~~ROCKWELL MEDICAL~~Rockwell Medical, ~~INC.~~ Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-23661	38-3317208	~~000-23661~~	~~38-3317208~~
(State or other jurisdictionof incorporation)			(Commission File Number)	(IRS EmployerIdentification No.)
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

30142 S. Wixom Road, Wixom, Michigan 48393

(Address of principal executive offices, including zip code)

(248) 960-9009

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each exchange on which registered
Common Stock, par value $0.0001		RMTI		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of ~~this~~the chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of ~~this~~ther chapter).

Emerging growth company ☐ ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ¨

Item 7 5.~~01 Regulation~~02 FDDeparture ~~Disclosure~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 12 17, 2025, Andrea Heslin Smiley resigned from the Board of Directors (the “Board”) of Rockwell Medical, Inc. ~~made~~(the ~~available~~“Company”) anand ~~updated~~all ~~corporate~~Board ~~presentation.~~committees Aon ~~copy~~which ofshe served, ~~the~~effective ~~corporate~~immediately. ~~presentation~~Ms. Smiley’s isresignation ~~furnished~~was ~~herewith~~not asthe ~~Exhibit~~result 99of any disagreement between Ms.1 Smiley and the ~~incorporated~~Company byon ~~reference~~any ~~herein~~matter relating to the Company’s operations, policies or practices.

InOn ~~accordance~~November 17, ~~with General Instruction B.2 of Form 8-K~~2025, the ~~information~~Board inappointed ~~this~~Joseph ~~Current~~H. ~~Report~~Dawson onto the ~~Form~~Board ~~8-K,~~as ~~including~~a ~~Exhibit~~Class II ~~99.1,~~director ~~shall~~to ~~not~~serve beuntil ~~deemed~~the toCompany’s be2026 ~~“filed”~~Annual ~~for~~Meeting ~~purposes~~ of ~~Section~~Stockholders 18and ofuntil ~~the~~his ~~Securities~~successor ~~Exchange~~is duly ~~Act~~elected ofand ~~1934~~qualified, aseffective ~~amended~~immediately. ~~(the~~Mr. Dawson ~~“Exchange~~has ~~Act”),~~also orbeen ~~otherwise~~appointed ~~subject~~ to ~~the~~serve ~~liabilities~~on ofthe ~~that~~Nominating ~~section,~~ and ~~shall~~Corporate ~~not~~Governance Committee beof ~~incorporated by reference into any registration statement or other document filed under~~ the ~~Securities~~Board ~~Act of 1933, as amended, or~~ (the ~~Exchange~~“Nominating ~~Act~~Committee”), ~~except~~effective ~~as shall be expressly set forth by specific reference in such filing~~immediately.

~~Item~~Mr. 9Dawson, aged 60, currently serves as an independent consultant.~~01 Financial~~ From ~~Statements~~May 2013 ~~and~~to ~~Exhibits~~June 2025, he served as President, North America of Nipro Medical Corporation. Prior to that, Mr. Dawson served as Senior Director of Corporate Account Sales for Cordis Corporation, then a subsidiary of Johnson & Johnson. Mr. Dawson earned his Bachelor of Science in Neurobiology from St. John’s University.

~~(d)~~In accordance with the Company’s non-employee director compensation policy, Mr. ~~Exhibits~~ Dawson will receive an annual cash retainer of $45,000 for his service as a director and $5,000 for service on the Nominating Committee, which will be pro-rated through the Company’s 2026 Annual Meeting of Stockholders. In addition, Mr. Dawson was granted an option to purchase 25,000 shares of the Company’s common stock at an exercise price equal to the closing price of the Company’s common stock on The ~~following~~Nasdaq ~~exhibit~~Capital isMarket ~~being~~on ~~furnished~~November 17, ~~herewith:~~2025, and 25,000 restricted stock units for his service as a director. The equity awards were made under the Company’s Amended and Restated 2018 Long Term Incentive Plan. The restricted stock units and the shares underlying the option will vest and become exercisable on November 17, 2026, subject to Mr. Dawson’s continued service to the Company. Mr. Dawson will enter into the Company’s standard form of indemnification agreement.

~~EXHIBIT~~There are no arrangements or understandings between Mr. ~~INDEX~~Dawson and any other persons pursuant to which he was elected as a director of the Company. There are no family relationships between Mr. Dawson and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Exhibit No.						Description
99.1						Rockwell Medical, Inc. Corporate Presentation, dated November 12, 2025
104						Cover Page Interactive Data File, formatted in INline XBRL and included as Exhibit 101.

SIGNATURE

~~SIGNATURE~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused ther report to be signed on its behalf by the undersigned hereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ROCKWELL MEDICAL, INC.

Date: November 18, 2025	By:	/s/ Mark Strobeck
		Mark Strobeck
		Chief Executive Officer

	ROCKWELL MEDICAL, INC.
Date: November 12, 2025	By:	/s/ Mark Strobeck
		Mark Strobeck
		Chief Executive Officer

Filing Compare · ROCKWELL MEDICAL, INC.